SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias board investigation into CEO Jensen Huangs alleged relationship with a woman reported to have Chinese intelligence ties has fueled concerns about governance, possible security implications, and leadership uncertainty. Traders are split between seeing the controversy as a serious overhang and treating the selloff as a buying opportunity based on confidence in Nvidias AI-chip business.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is under pressure ahead of its Q3 results, with traders split between optimism about growth and concern over further downside. The Eli Lilly obesity-drug partnership adds to the debate, particularly over how branded GLP-1 sales could affect growth and margins.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors HOPE-3 cardiac results for deramiocel received an American Heart Association research award, drawing attention as traders focus on the Nov. 22 FDA decision on the DMD therapy. The community is largely optimistic about approval, citing the trial data and physician support, while others stress the uncertainty after the advisory panels negative vote on the cardiac indication; the award itself does not determine FDA approval.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics strong third-quarter results and raised full-year revenue outlook, driven by BRIUMVIs commercial growth, are the main focus; traders largely welcomed the update and bought a sharp post-earnings dip, though some see the volatile reaction as sell-the-news behavior. The upcoming Phase 3 readout for subcutaneous BRIUMVI is viewed as the next major catalyst.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A sharp, high-volume run-up ahead of TTDs Q3 report is driving attention, with traders speculating about short covering or an earnings leakneither is confirmed. Bulls see potential for a squeeze or turnaround, while skeptics expect the rally to fade amid weak growth expectations and past post-earnings selloffs.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

SITC updates on Candels cancer programsespecially CAN-2409s systemic immune activation and biodistribution data in prostate cancerare renewing interest and viewed by bullish traders as support for the planned BLA filing. Others remain cautious, noting that biomarker findings do not replace the Phase 3 evidence and questioning the filing timeline and managements transparency.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs sharp rebound is being attributed to Oppenheimers upgrade and optimism about its AI and data-center business, with Googles use of EPYC processors adding to the bullish case. Nvidia leadership-investigation headlines have also fueled speculation about a rotation into AMD, though traders debate whether the rally is sustainable given valuation concerns and the size of the move.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axons sharp selloff follows a Q3 earnings miss and a lower full-year outlook, with federal Dedrone deployments delayed out of the forecast period. Traders are split between calling the drop an overreaction and buying the dip, and warning that the high valuation and weakening outlook could mean further downside.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

A sharp semiconductor selloff and concerns about AI and data-center spending are driving interest in SOXS, the 3x inverse semiconductor ETF. Traders are split between expecting further declines in chip stocks and anticipating a rebound, while noting the funds leveraged daily resets can magnify losses in volatile markets.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs preliminary third-quarter results, which traders characterize as a revenue beat with strong growth, have sparked a sharp rally. Bulls are celebrating the update and speculating that short covering is amplifying the move, while some question whether the gains will hold through the full earnings release.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ABCL  
Q3 earnings after market close. 
Focus on clinical updates for ABCL635, which has generated significant enthusiasm following breakthrough PH2 data in menopausal hot flashes. 
ABCL expects a loss of 17 cents per share on revenue of $6.21 million for the Q. While that would represent sequential improvement from the prior q’s loss of 18 cents/share, revenue of $4.1 million, it also reflects a y-o-y revenue decline of 31% as ABCL transitions from its antibody discovery platform business to a pipeline-focused biotech. 
Analysts rate the stock a Strong Buy,consensus PT of $17.17.  
 
Jefferies, UBS, JPMorgan initiated coverage in recent weeks with Buy ratings and price targets ranging from $17 to $21, all citing ABCL635’s commercial potential.  
The monthly subcutaneous antibody for vasomotor symptoms showed an 83% reduction in moderate-to-severe hot flashes versus 33% for placebo in PH2 results announced in AUG, prompting analysts to describe the efficacy as &quot;unprecedented&quot; and &quot;best-in-class...&quot;

Maria LaPaz

Stonk Trades

Justin

Maikel van den Heuvel

Johnny nunan

StockTwits Web

AbCellera Biologics Inc

  
Q3 earnings after market close. 
Focus on clinical updates for ABCL635, which has generated significant enthusiasm following breakthrough PH2 data in menopausal hot flashes. 
ABCL expects a loss of 17 cents per share on revenue of $6.21 million for the Q. While that would represent sequential improvement from the prior q’s loss of 18 cents/share, revenue of $4.1 million, it also reflects a y-o-y revenue decline of 31% as ABCL transitions from its antibody discovery platform business to a pipeline-focused biotech. 
Analysts rate the stock a Strong Buy,consensus PT of $17.17.  
 
Jefferies, UBS, JPMorgan initiated coverage in recent weeks with Buy ratings and price targets ranging from $17 to $21, all citing ABCL635’s commercial potential.  
The monthly subcutaneous antibody for vasomotor symptoms showed an 83% reduction in moderate-to-severe hot flashes versus 33% for placebo in PH2 results announced in AUG, prompting analysts to describe the efficacy as "unprecedented" and "best-in-class..."